Transcending the biomarker mindset: Deciphering disease mechanisms at the single cell level

Current Opinion in Chemical Biology

Volumn 10, Issue 1, 2006, Pages 20-27

  Danna, Erika A ^a   Nolan, Garry P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BCR ABL PROTEIN; BIOLOGICAL MARKER; IMATINIB; JANUS KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CARCINOGENESIS; CELL ASSAY; CHRONIC MYELOID LEUKEMIA; COMBINED IMMUNODEFICIENCY; CORRELATION ANALYSIS; DISEASE COURSE; DNA DAMAGE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRACELLULAR SPACE; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN PROCESSING; PROTEIN TARGETING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VALIDATION PROCESS; VIRUS INFECTION;

BIOLOGICAL MARKERS; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; NEOPLASMS; NERVOUS SYSTEM DISEASES; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 32044450268     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2005.12.021     Document Type: Review

References (45)

1. M. Baker In biomarkers we trust? Nat Biotechnol 23 2005 297 304 This review provides a more in-depth look at various types of biomarkers and discusses recent successes and failures in the discovery and application of novel biomarkers.
2. Q.Y. He, and J.F. Chiu Proteomics in biomarker discovery and drug development J Cell Biochem 89 2003 868 886
3. E.F. Petricoin III, V.E. Bichsel, V.S. Calvert, V. Espina, M. Winters, L. Young, C. Belluco, B.J. Trock, M. Lippman, and D.A. Fishman Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy J Clin Oncol 23 2005 3614 3621 This manuscript highlights the use of biomarkers in the development of merged diagnostics-therapy wherein patients are diagnosed using molecular markers that indicate disease class and are assigned therapy regimens on the basis of this classification.
4. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 2003 566 580
5. T. Hunter Signaling-2000 and beyond Cell 100 2000 113 127
6. Z. Zhang, M. Li, E.R. Rayburn, D.L. Hill, R. Zhang, and H. Wang Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules Am J Pharmacogenomics 5 2005 247 257
7. Z. Zhang, M. Li, E.R. Rayburn, D.L. Hill, R. Zhang, and H. Wang Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases Am J Pharmacogenomics 5 2005 173 190
8. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
9. R.H. Buckley Primary immunodeficiency diseases due to defects in lymphocytes N Engl J Med 343 2000 1313 1324
10. J.J. O'Shea, M. Husa, D. Li, S.R. Hofmann, W. Watford, J.L. Roberts, R.H. Buckley, P. Changelian, and F. Candotti Jak3 and the pathogenesis of severe combined immunodeficiency Mol Immunol 41 2004 727 737
11. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W: A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005, in press.
12. J. Tao, H. Van Esch, M. Hagedorn-Greiwe, K. Hoffmann, B. Moser, M. Raynaud, J. Sperner, J.P. Fryns, E. Schwinger, and J. Gecz Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation Am J Hum Genet 75 2004 1149 1154
13. M.P. Playford, and M.D. Schaller The interplay between Src and integrins in normal and tumor biology Oncogene 23 2004 7928 7946
14. Y.P. Lim Mining the tumor phosphoproteome for cancer markers Clin Cancer Res 11 2005 3163 3169
15. S. Wong, and O.N. Witte The BCR-ABL story: bench to bedside and back Annu Rev Immunol 22 2004 247 306
16. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 2001 355 365
17. B.J. Druker STI571 (Gleevec) as a paradigm for cancer therapy Trends Mol Med 8 2002 S14 S18 This article reviews one of the first major successes of kinase-specific inhibitors for disease treatment and provides insight for future development of targeted molecular therapies.
18. R.P. Araujo, C. Doran, L.A. Liotta, and E.F. Petricoin III Network-targeted combination therapy: a new concept in cancer treatment Drug Discov Today Therap Strat 1 2004 425 433 This article describes the merits of developing molecular therapeutics targeting multiple components of a signaling network and compares this approach with other combination therapies.
19. M.R. Green Targeting targeted therapy N Engl J Med 350 2004 2191 2193
20. P. Cohen Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1 2002 309 315
21. C.B. Thompson Apoptosis in the pathogenesis and treatment of disease Science 267 1995 1456 1462
22. J.M. Irish, R. Hovland, P.O. Krutzik, O.D. Perez, O. Bruserud, B.T. Gjertsen, and G.P. Nolan Single cell profiling of potentiated phospho-protein networks in cancer cells Cell 118 2004 217 228 This paper describes the use of phospho-specific flow cytometry for the profiling of signaling networks within acute myeloid leukemia cells. It demonstrates the ability to construct patient-specific network maps, allowing the stratification of patients with respect to disease outcome and other clinical variables.
23. P.O. Krutzik, and G.P. Nolan Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events Cytometry A 55 2003 61 70
24. P.O. Krutzik, M.R. Clutter, and G.P. Nolan Coordinate analysis of murine immune cell surface markers and intracellular phosphoproteins by flow cytometry J Immunol 175 2005 2357 2365
25. Perez OD, Nolan GP: Phospho-proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single cell level. Immunol Rev 2005, in press.
26. O.D. Perez, D. Mitchell, G. Gao, L. Li, R. Campos, and G.P. Nolan Multiparameter analysis of intracellular phospho-epitopes in immunophenotyped cell populations by flow cytometry Curr Protocol Cytometry 2005 Unit 6.20
27. P.O. Krutzik, J.M. Irish, G.P. Nolan, and O.D. Perez Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications Clin Immunol 110 2004 206 221
28. K. Sachs, O. Perez, D. Pe'er, D.A. Lauffenburger, and G.P. Nolan Causal protein-signaling networks derived from multiparameter single-cell data Science 308 2005 523 529 This paper demonstrates that automated machine learning can be applied to signaling profiles to determine signaling maps from patient samples.
29. S.P. Perfetto, P.K. Chattopadhyay, and M. Roederer Seventeen-colour flow cytometry: unravelling the immune system Nat Rev Immunol 4 2004 648 655
30. S.F. Ibrahim, and G. van den Engh High-speed cell sorting: fundamentals and recent advances Curr Opin Biotechnol 14 2003 5 12
31. M.R. Clutter, P.O. Krutzik, and G.P. Nolan Phospho-specific flow cytometry in drug discovery Drug Discov Today Technologies 2 2005 295 302
32. Perez OD, Nolan GP: Appreciating the heterogeneity in autoimmune disease: multiparameter assessment of Intracellular signaling mechanisms. New York Acad Sci 2005, in press.
33. H.E. Farrell, and N.J. Davis-Poynter From sabotage to camouflage: viral evasion of cytotoxic T lymphocyte and natural killer cell-mediated immunity Semin Cell Dev Biol 9 1998 369 378
34. M.D. Hazenberg, S.A. Otto, B.H. van Benthem, M.T. Roos, R.A. Coutinho, J.M. Lange, D. Hamann, M. Prins, and F. Miedema Persistent immune activation in HIV-1 infection is associated with progression to AIDS Aids 17 2003 1881 1888
35. M.P. Eggena, B. Barugahare, N. Jones, M. Okello, S. Mutalya, C. Kityo, P. Mugyenyi, and H. Cao Depletion of regulatory T cells in HIV infection is associated with immune activation J Immunol 174 2005 4407 4414
36. A. Manninen, and K. Saksela HIV-1 Nef interacts with inositol trisphosphate receptor to activate calcium signaling in T cells J Exp Med 195 2002 1023 1032
37. J.F. Fortin, C. Barat, Y. Beausejour, B. Barbeau, and M.J. Tremblay Hyper-responsiveness to stimulation of human immunodeficiency virus-infected CD4+ T cells requires Nef and Tat virus gene products and results from higher NFAT, NF-kappaB, and AP-1 induction J Biol Chem 279 2004 39520 39531
38. J.T. Merrill, D. Erkan, and J.P. Buyon Challenges in bringing the bench to bedside in drug development for SLE Nat Rev Drug Discov 3 2004 1036 1046
39. E.M. Posadas, F. Simpkins, L.A. Liotta, C. MacDonald, and E.C. Kohn Proteomic analysis for the early detection and rational treatment of cancer - realistic hope? Ann Oncol 16 2005 16 22
40. C.A. Granville, and P.A. Dennis An overview of lung cancer genomics and proteomics Am J Respir Cell Mol Biol 32 2005 169 176
41. E. Salih Phosphoproteomics by mass spectrometry and classical protein chemistry approaches Mass Spectrom Rev 24 2005 828 846
42. M.V. Metodiev, A. Timanova, and D.E. Stone Differential phosphoproteome profiling by affinity capture and tandem matrix-assisted laser desorption/ionization mass spectrometry Proteomics 4 2004 1433 1438
43. S.B. Ficarro, M.L. McCleland, P.T. Stukenberg, D.J. Burke, M.M. Ross, J. Shabanowitz, D.F. Hunt, and F.M. White Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae Nat Biotechnol 20 2002 301 305
44. Y. Oda, T. Nagasu, and B.T. Chait Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome Nat Biotechnol 19 2001 379 382
45. M. Roederer, A. Treister, W. Moore, and L.A. Herzenberg Probability binning comparison: a metric for quantitating univariate distribution differences Cytometry 45 2001 37 46